Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
The latest clinical data suggest that the advanced CAR-T therapies could improve long-term treatment outcomes, potentially influencing future market o...
Read Full Article →